Symptomatic improvement versus objective urethral functional recovery following stem cell-based therapy for stress urinary incontinence: a systematic review
DOI:
https://doi.org/10.65759/w349c049Keywords:
stress urinary incontinence, cell therapy, regenerative medicine, urethral sphincter, muscle-derived cellsAbstract
Background: Stem cell-based urethral injection has been proposed as a regenerative treatment for stress urinary incontinence (SUI), and symptom relief does not necessarily establish recovery of urethral sphincter function. Objective: To compare patient-centred symptomatic improvement with direct assessment of urethral functional recovery after cell-based treatment for female SUI. Method: PubMed/MEDLINE, Scopus, Web of Science Core Collection, and the Cochrane Library were searched from inception through 2026-05-31. Human interventional studies of adult women with SUI treated with a stem cell, muscle precursor cell, adipose-derived stem-cell, stromal vascular fraction, or related autologous regenerative cell product were eligible. Retracted reports were excluded. Two reviewers independently screened records, extracted study-level data, linked reports from the same cohort, and synthesized the findings narratively. Symptom outcomes included leakage episodes, pad tests, cough stress testing, validated questionnaires, and quality of life. Direct functional recovery required urethral pressure or length measurements, sphincter contractility, or structural imaging interpreted alongside function. Results: Twenty-two original reports were identified. Symptom measures improved, including pad weight, cough stress test, incontinence episodes, and questionnaire scores. Direct urethral measurements were sparse and heterogeneous. One phase I study documented increased functional urethral length and external sphincter diameter alongside improved ICIQ-UI-SF scores, whereas a 38-participant study reported persistent symptom benefit without overall improvement in urodynamic urethral properties. In the largest blinded trial, the primary symptom endpoint did not differ from placebo. An electrical-stimulation plus cell-implantation trial favored cellular arms against placebo on symptom endpoints without direct physiologic confirmation. Conclusion: Current findings support a short-term symptom signal and acceptable procedural tolerability; they do not establish consistent objective urethral functional regeneration. Future trials require standardized cell-product reporting, blinded comparison, direct pressure-based and imaging outcomes, and durable follow-up.
References
1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4-20. doi:10.1002/nau.20798.
2. Aoki Y, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017;3:17097. doi:10.1038/nrdp.2017.97.
3. Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2018;10(10). doi:10.1002/14651858.CD005654.pub4.
4. Ford AA, Rogerson L, Cody JD, Aluko P, Ogah JA. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev. 2017;7(7). doi:10.1002/14651858.CD006375.pub4.
5. Lin CS, Lue TF. Stem cell therapy for stress urinary incontinence: a critical review. Stem Cells Dev. 2012;21(6):834-843. doi:10.1089/scd.2011.0621.
6. Hart ML, Izeta A, Herrera-Imbroda B, Amend B, Brinchmann JE. Cell therapy for stress urinary incontinence. Tissue Eng Part B Rev. 2015;21(4):365-376. doi:10.1089/ten.TEB.2014.0627.
7. Vinarov A, Atala A, Yoo J, Slusarenco R, Zhumataev M, Zhito A, et al. Cell therapy for stress urinary incontinence: present-day frontiers. J Tissue Eng Regen Med. 2018;12(2). doi:10.1002/term.2444.
8. Barakat B, Franke K, Schakaki S, Hijazi S, Hasselhof V, Vögeli TA. Stem cell applications in regenerative medicine for stress urinary incontinence: a review of effectiveness based on clinical trials. Arab J Urol. 2020;18(3):194-205. doi:10.1080/2090598X.2020.1750864.
9. Klapper-Goldstein H, Tamam S, Sade S, Weintraub AY. A systematic review of stem cell therapy treatment for women suffering from stress urinary incontinence. Int J Gynaecol Obstet. 2022;157(1):19-30. doi:10.1002/ijgo.13769.
10. Carr LK, Steele D, Steele S, Wagner D, Pruchnic R, Jankowski R, et al. 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(6):881-883. doi:10.1007/s00192-007-0553-z.
11. Lee CN, Jang JB, Kim JY, Koh C, Baek JY, Lee KJ. Human cord blood stem cell therapy for treatment of stress urinary incontinence. J Korean Med Sci. 2010;25(6):813-816. doi:10.3346/jkms.2010.25.6.813.
12. Sèbe P, Doucet C, Cornu JN, Ciofu C, Costa P, de Medina SG, et al. Intrasphincteric injections of autologous muscular cells in women with refractory stress urinary incontinence: a prospective study. Int Urogynecol J. 2011;22(2):183-189. doi:10.1007/s00192-010-1255-5.
13. Shirvan MK, Alamdari DH, Mahboub MD, Ghanadi A, Rahimi HR, Seifalian AM. A novel cell therapy for stress urinary incontinence, short-term outcome. Neurourol Urodyn. 2013;32(4):377-382. doi:10.1002/nau.22301.
14. Blaganje M, Lukanović A. Intrasphincteric autologous myoblast injections with electrical stimulation for stress urinary incontinence. Int J Gynaecol Obstet. 2012;117(2):164-167. doi:10.1016/j.ijgo.2011.11.029.
15. Carr LK, Robert M, Kultgen PL, Herschorn S, Birch C, Murphy M, et al. Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study. J Urol. 2013;189(2):595-601. doi:10.1016/j.juro.2012.09.028.
16. Stangel-Wojcikiewicz K, Jarocha D, Piwowar M, Jach R, Uhl T, Basta A, et al. Autologous muscle-derived cells for the treatment of female stress urinary incontinence: a 2-year follow-up of a Polish investigation. Neurourol Urodyn. 2014;33(3):324-330. doi:10.1002/nau.22404.
17. Peters KM, Dmochowski RR, Carr LK, Robert M, Kaufman MR, Sirls LT, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol. 2014;192(2):469-476. doi:10.1016/j.juro.2014.02.047.
18. Gräs S, Klarskov N, Lose G. Intraurethral injection of autologous minced skeletal muscle: a simple surgical treatment for stress urinary incontinence. J Urol. 2014;192(3):850-855. doi:10.1016/j.juro.2014.04.005.
19. Kuismanen K, Sartoneva R, Haimi S, Mannerström B, Tomás E, Miettinen S, et al. Autologous adipose stem cells in treatment of female stress urinary incontinence: results of a pilot study. Stem Cells Transl Med. 2014;3(8):936-941. doi:10.5966/sctm.2013-0197.
20. Arjmand B, Safavi M, Heidari R, Aghayan H, Bazargani ST, Dehghani S, et al. Concomitant transurethral and transvaginal-periurethral injection of autologous adipose derived stem cells for treatment of female stress urinary incontinence: a phase one clinical trial. Acta Med Iran. 2017;55(6):368-374.
21. Jankowski RJ, Tu LM, Carlson C, Robert M, Carlson K, Quinlan D, et al. A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence. Int Urol Nephrol. 2018;50(12):2153-2165. doi:10.1007/s11255-018-2005-8.
22. Sharifiaghdas F, Zohrabi F, Moghadasali R, Shekarchian S, Jaroughi N, Bolurieh T, et al. Autologous muscle-derived cell injection for treatment of female stress urinary incontinence: a single-arm clinical trial with 24-months follow-up. Urol J. 2019;16(5):482-487. doi:10.22037/uj.v0i0.4736.
23. Garcia-Arranz M, Alonso-Gregorio S, Fontana-Portella P, Bravo E, Diez Sebastian J, Fernandez-Santos ME, et al. Two phase I/II clinical trials for the treatment of urinary incontinence with autologous mesenchymal stem cells. Stem Cells Transl Med. 2020;9(12):1500-1508. doi:10.1002/sctm.19-0431.
24. Maene A, Deniz G, Bouland C, Lagneaux L, Philippart P, Buxant F. Suburethral implantation of autologous regenerative cells for female stress urinary incontinence management: results of a pilot study. Eur J Obstet Gynecol Reprod Biol. 2022;278:38-44. doi:10.1016/j.ejogrb.2022.08.028.
25. Blaganje M, Lukanović A. The effect of skeletal muscle-derived cells implantation on stress urinary incontinence and functional urethral properties in female patients. Int J Gynaecol Obstet. 2022;157(2):444-451. doi:10.1002/ijgo.13853.
26. Schmid FA, Prange JA, Kozomara M, Betschart C, Sousa RA, Steinke N, et al. Transurethral injection of autologous muscle precursor cells for treatment of female stress urinary incontinence: a prospective phase I clinical trial. Int Urogynecol J. 2023;34(9):2197-2206. doi:10.1007/s00192-023-05514-4.
27. Mahboubeh M, Hamid P, Azar D, Mohammad Ali B, Alireza F, Mohsen B. Short and medium-term results of the autologous adult mucosa stem cell therapy compared with mini-sling surgery in the treatment of women’s stress urinary incontinence: a randomized clinical trial. Curr Stem Cell Res Ther. 2023;18(2):276-283. doi:10.2174/1574888X17666220330010453.
28. Kaufman MR, Goldman HB, Chermansky CJ, Dmochowski R, Kennelly MJ, Peters KM, et al. Iltamiocel autologous cell therapy for the treatment of female stress urinary incontinence: a double-blind, randomized, stratified, placebo-controlled trial. Neurourol Urodyn. 2024;43(8):2290-2299. doi:10.1002/nau.25588.
29. Rose A, Rübben H. Implantation of autologous skeletal muscle-derived cells combined with electrical stimulation in patients with stress urinary incontinence. Int Urogynecol J. 2025;36(3):703-713. doi:10.1007/s00192-025-06079-0.
30. Dutta R, Yoo JJ, Atala A, Day MC, Evans R, Langefeld CD, et al. Autologous muscle precursor cell injection into the bladder neck improves the symptoms of stress urinary incontinence in adult females. Stem Cells Transl Med. 2025;14(10). doi:10.1093/stcltm/szaf039.
31. Souza RC, Bortolini MAT, Melino Y, de Godoy JAP, Alvarez K, Oliveira D, et al. Stem cell therapy for female stress urinary incontinence: results, limitations and lessons learned from a pilot clinical study. PLoS One. 2026;21(2). doi:10.1371/journal.pone.0342452.
32. Kleinert S, Horton R. Retraction—autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. Lancet. 2008;372(9641):789-790. doi:10.1016/S0140-6736(08)61320-3.
33. Ismail S, Morin M, Tu LM. Assessment of the effects of autologous muscle-derived cell injections on urethral sphincter morphometry using 3D/4D ultrasound. World J Urol. 2020;38(11):2881-2889. doi:10.1007/s00345-020-03076-4.
34. Gotoh M, Yamamoto T, Kato M, Majima T, Toriyama K, Kamei Y, et al. Regenerative treatment of male stress urinary incontinence by periurethral injection of autologous adipose-derived regenerative cells: 1-year outcomes in 11 patients. Int J Urol. 2014;21(3):294-300. doi:10.1111/iju.12266.
35. Gotoh M, Shimizu S, Yamamoto T, Ishizuka O, Yamanishi T, Mizokami A, et al. Regenerative treatment for male stress urinary incontinence by periurethral injection of adipose-derived regenerative cells: outcome of the ADRESU study. Int J Urol. 2020;27(10):859-865. doi:10.1111/iju.14311.
